Results 151 to 160 of about 102,475 (311)
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini +4 more
wiley +1 more source
The Swiss Haemophilia Registry–Report From the First 8 Years
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch +8 more
wiley +1 more source
ABSTRACT Introduction Monitoring extended half‐life (EHL) factor (F) VIII and FIX products is complex, as discrepant results are obtained in different laboratory assays. Aim To provide an overview on assay accuracy based on a re‐assessment of previously published data as well as laboratory results of EHL spiking experiments for specific factor assays ...
An K. Stroobants +5 more
wiley +1 more source
Ristocetin-induced platelet aggregation, von Willebrand factor and coagulation factor VIII of 170 children with essential arterial hypertension and 40 healthy children were investigated.
M. V. Gomellya
doaj
Seventh Åland Island Meeting on von Willebrand Disease
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila +17 more
wiley +1 more source
Beyond Standard Half‐Life: Real‐world Pharmacokinetics of Efanesoctocog Alfa in a Single Centre
ABSTRACT Introduction Efanesoctocog alfa (EFA) is an ultra–extended half‐life factor VIII (FVIII) developed to address limitations of conventional prophylaxis in haemophilia A. Although the XTEND trials reported low interindividual pharmacokinetic (PK) variability, real‐world data remain important to better characterize PK profiles across patient ...
Laurent Sattler +6 more
wiley +1 more source
Small Bowel Lesions and Bleeding Risk in Hemodialysis Patients: A Narrative Review
ABSTRACT Background Gastrointestinal bleeding is very common among hemodialysis patients. This high bleeding risk is caused by uremic platelet dysfunction, vascular fragility, intradialytic hemodynamic instability, and widespread antithrombotic therapy.
Andreas Smyrlis +3 more
wiley +1 more source
ABSTRACT Introduction Investigator‐led research and quality improvement initiatives have led to important improvements in the diagnostic assessment of platelet function disorders (PFD). Methods Personal reflections were used to summarize our contributions to knowledge on PFD diagnostic assessment, pathogenesis, and bleeding risks.
Catherine P. M. Hayward
wiley +1 more source
ABSTRACT Borderline prolongation of routine clotting assays—particularly the activated partial thromboplastin time (aPTT)—is a common interpretative challenge in laboratory hematology. These reproducible but mildly prolonged results often lie just beyond the upper reference limit and can trigger unnecessary follow‐up, delays, or misinterpretation ...
Nikolaos Androulakis +3 more
wiley +1 more source
Allele-selective von Willebrand factor silencing. [PDF]
Eikenboom J, Linthorst N, Jongejan Y.
europepmc +1 more source

